Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.

NCT Number	NCT04925609
Lead Sponsor	Princess Maxima Center for Pediatric Oncology Collaborators: Takeda
Conditions	Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor
Enrollment	65 participants
Start Date	2022-08-18
Primary Completion	2033-12 (estimated)
Study Completion	2033-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-05